Study of Semaglutide Treatment for Adults with Psoriasis and Obesity or Overweight with Weight-Related Health Conditions

What this Trial Is About

Researchers are investigating the effects of semaglutide, a medication that may help with weight loss and has potential anti-inflammatory benefits, on adults with both psoriasis and obesity. Psoriasis patients with obesity often face more severe disease and higher risks such as psoriatic arthritis. This open-label, single-arm pilot trial aims to explore whether semaglutide can reduce psoriasis severity alongside weight loss. The study is sponsored by The University of Hong Kong and targets Chinese adults with moderate to severe psoriasis and obesity or overweight conditions. Participants will receive semaglutide injections once weekly, starting at 0.25 mg and continuing up to 2.0 mg over 24 weeks. This treatment is combined with lifestyle changes including a reduced-calorie diet and increased physical activity. Standard psoriasis care will continue throughout the study. The trial includes a 4-week screening period before treatment and a 12-week safety follow-up after the final dose to monitor participant health. During the approximately 36 weeks of participation, patients will undergo evaluations including the Psoriasis Area and Severity Index PASI to measure changes in skin condition. Researchers will also monitor treatment adherence, safety, and any side effects. The main goal is to assess the change in psoriasis severity before and after semaglutide treatment. The study allows previous systemic immunosuppressant use and focuses on adults aged 18 to 75 years with specific body mass index criteria and stable psoriasis treatment.

Effect of Semaglutide in Patients With Psoriasis and Obesity